ChemPartner
22.12.2023 22:02:41 CET | ACCESS Newswire | Press release
Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs
SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 / ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database. This innovative platform serves as a centralized hub, empowering ChemPartner's clientele with seamless access to a wealth of information on the organization's cutting-edge preclinical platforms. The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Screenshot of the online Biology Database from ChemPartner
ChemPartner's renowned biology and pharmacology department, known for its vanguard oncology, immunology, CNS, and metabolic services, has curated an extensive collection of in vitro and in vivo models. The database boasts over 2,000 biochemistry assays, 800 cell lines, 500 patient-derived xenograft (PDX) models, 350 cell-derived xenograft (CDX) models, and 50 syngeneic models. Each model is meticulously characterized with comprehensive data encompassing genomics, pharmacology, histopathology, and relevant clinical information.
Cell Line Models - ChemPartner Biology Database
To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages. We are delighted to announce that the first stage, featuring cell line data, is now live on https://database.chempartner.com. Subsequent stages will include CDX, syngeneic, and PDX models, followed by biochemistry data.
The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database. This revolutionary resource offers an array of features, including:
- Unified Data Hub: Integration of dispersed tumor model data into a centralized database for efficient management and retrieval, simplifying user access to diverse tumor models.
- Detailed Annotations: Each model is accompanied by intricate annotations including genomics, pathology, and pharmacology data, enabling rapid understanding of model characteristics and suitability for specific research needs.
- Rapid Search and Filtering: Multidimensional search and filtering capabilities empower researchers to swiftly locate models based on cancer type, genomic features, drug sensitivity, and more.
- Data Analysis and Mining: Robust tools facilitate tasks like drug mechanism analysis and biomarker discovery through differential gene expression and drug sensitivity analyses, supporting informed research decisions.
- Data Visualization: Intuitive charts, statistics, and visualization tools present complex data clearly and concisely, aiding in model selection and analysis.
Dr. Lilly Xu, President of Shanghai ChemPartner, expressed enthusiasm about the launch saying, "We are excited to provide our customers with access to this powerful new resource. This comprehensive database will make it easier for our customers to find and use the right models for their research, propelling drug development towards new heights with better precision, efficacy, and efficiency."
-
About ChemPartner
ChemPartner is a leading global CRO and CDMO providing drug discovery, development, and manufacturing services to the pharmaceutical and biotechnology industries. With a team of over 2,000 scientists across multiple countries, ChemPartner offers a comprehensive range of services including preclinical pharmacology, toxicology, drug metabolism and pharmacokinetics, chemistry development, and biologics development. For more information, please visit https://chempartner.com and connect with ChemPartner on LinkedIn, X, and YouTube.
Contact Information
Sarah Stapleton
Marketing Director
news@chempartner.com
6504199974
Related Images
|
SOURCE: ChemPartner
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi Signs Credit Support Agreement with AMD and Announces Partnership13.10.2026 14:00:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / October 13, 2026 / Fermi Inc. (Nasdaq:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced that it has signed a credit support agreement with AMD, the high performance and adaptive computing leader, supporting a lease for phase one of Fermi's Project Matador energy and AI buildout in Carson County, Texas, with 222 megawatts (MW) of gross power capacity in line with Fermi's first customer lease as announced on August 10, 2026. The agreement represents a key milestone toward securing project financing. The companies have also signed an agreement outlining a partnership and framework for future expansion of up to 650 MW of gross power capacity. Lee McIntire, Fermi Chief Executive Officer said, "We are thrilled to partner with AMD as we advance development at Project Matador. Our strategic partnership establishes a framework for phases two and three. We have the land, the permits, the water, the power equipment, and the fib
Digi Power X Announces $200 Million Debt Financing Commitment to Support Completion of Alabama AI Data Center and Provides Expansion Update13.10.2026 13:30:00 CEST | Press release
MIAMI BEACH, FL / ACCESS Newswire / October 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today announced that it has received a commitment letter from a major lending institution for US$200 million in debt financing to support the development of its 40 MW AI data center in Columbiana, Alabama. The financing, syndicated by Goldman Sachs, is expected to close within 90 days, subject to definitive documentation and satisfaction of various conditions, including the lender's completion of its diligence efforts. The financing is to be structured at a project special purpose vehicle ("SPV") level, with an unsecured Company guarantee through project completion and other limited matters. Proceeds are intended to support completion of the Alabama project and related project costs, helping preserve corporate liquidity, mitigate shareholder dilution and position the Company to pursue additional customer co
Akkodis Brings Multilingual Intelligence to Mercedes-AMG PETRONAS Formula One Team races13.10.2026 06:45:00 CEST | Press release
ZURICH / ACCESS Newswire / October 13, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, today announced the deployment of a multilingual AI solution that enables international guests in the Mercedes-AMG PETRONAS Formula One Team Viewing Gallery to access real-time translated team radio and race commentary, event information and Formula 1 (F1) communications in their preferred language. Built using Akkodis' AI-Core system, the solution processes information directly at the circuit, delivering responsive, low-latency real-time transcription and translation services. The deployment highlights a growing shift in how organizations operate, bringing intelligence closer to where information is generated and decisions are made. Debuting at the Formula 1 Italian Grand Prix in Monza, the solution demonstrates how such systems can enhance real-world experiences in demanding, fast-paced and information-rich environments. For international guests in th
Fermi Announces Third Quarter 2026 Earnings Release and Call Date12.10.2026 22:01:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / October 12, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced that it plans to release third quarter 2026 financial results at 7 a.m. Eastern Time / 12 p.m. British Time on Thursday, November 12, 2026. This announcement will be followed by an earnings conference call at 9 a.m. Eastern Time / 2 p.m. British Time. The Company's earnings release and supplemental information will be posted to the Investors section of the Company's website prior to the conference call. To join the live conference call, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally approximately 15 minutes prior to the scheduled start time and refer to conference code 176575. The call will also be webcast in a listen-only mode and can be accessed through the Investor Relations Events & Presentations page of Fermi's website. A replay of the webcast will be available for a period of one year. Investor Contact Barr
Chervon Names Charlie Harte Director of Field Sales & Recruiting - Canada12.10.2026 16:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Charlie Harte joins Chervon as Director of Field Sales and Recruiting - Canada, effective Monday, October 12, 2026, reporting to Neil Harrison, VP/MD Sales and Marketing - Canada. Harte brings 15+ years of experience in the Canadian power tools, outdoor power equipment, and hand tool market. Additionally, he has 6+ years of experience selling into the commercial plumbing arena. Early in his career, Harte spent six years at Black and Decker growing into the National Sales and Marketing Manager position for B&D Canada. He subsequently became Director of Sales for Irwin Industrial Tools and then became a Director of Sales for Milwaukee Canada. Harte moved into the VP Sales position for Uponor Advanced Plumbing Solutions. Harte has an impressive track record in field sales leadership and strategic account development. He is known for his ability to build and manage high-performance sales teams throughout Canada. "Charlie brings an outst
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom